Table 1 Clinical characteristics of 50 patients with t-MN treated with azacitidine
From: Outcome of therapy-related myeloid neoplasms treated with azacitidine
Patient Characteristics | n ( range) |
|---|---|
Median age (years, median, range) | 66 (37–84) |
Sex (M/F) | 28/22 |
ECOG PS | |
0–1 | 46 |
2-3 | 4 |
Type of t-MDS/AML according to the WHO | |
- AML: | 16 |
BM-blasts 20-29% | 5 |
BM-blasts ≥30% | 11 |
- MDS: | 34 |
RCMD | 12 |
RAEB1 | 9 |
RAEB 2 | 13 |
Primary malignancy : | |
- Lymphoproliferative disease | 19 |
- Multiple myeloma | 3 |
- Chronic myeloproliferative disease | 5 |
- Breast cancer | 6 |
- Urogenital | 9 |
- Other | 8 |
Treatment for Primary Malignancy: | |
- Chemotherapy | 27 |
- Radiotherapy | 9 |
- RTx + CTx | 14 |
Median latency between primary cytotoxic therapy and t-MN diagnosis (years) | 6.1 (0.2-29.8) |
Median value at diagnosis (range): | |
- White blood cell counts (109 /L) | 2.6 (0.1-26) |
- Platelets (109 /L) | 69.5 (5–395) |
- Bone Marrow blasts (%) | 13 (1–90) |
- LDH (UI/L) | 403 (130–2498) |
Median interval between t-MN diagnosis and AZA treatment (months) | 1.8 (0–39) |
Response to treatment: | |
- Overall response: | 20 (42%) |
- CR | 10 (21%) |
- PR | 2 (4.2%) |
- HI | 8 (16.7%) |
- Stable disease | 15 (31%) |
- Progression | 13 (27%) |
- Not evaluable | 2 |
Median cycles number for response | 3 (range 1–6) |